このアイテムのアクセス数: 43

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
s00262-024-03929-6.pdf5.08 MBAdobe PDF見る/開く
完全メタデータレコード
DCフィールド言語
dc.contributor.authorSuzuki, Harukaen
dc.contributor.authorHamada, Koheien
dc.contributor.authorHamanishi, Junzoen
dc.contributor.authorUeda, Akihikoen
dc.contributor.authorMurakami, Ryusukeen
dc.contributor.authorTaki, Manaen
dc.contributor.authorMizuno, Rinen
dc.contributor.authorWatanabe, Koichien
dc.contributor.authorSato, Hanakoen
dc.contributor.authorHosoe, Yukoen
dc.contributor.authorIto, Hiroakien
dc.contributor.authorYamanoi, Kojien
dc.contributor.authorYoshitomi, Hiroyukien
dc.contributor.authorKakiuchi, Nobuyukien
dc.contributor.authorYamaguchi, Kenen
dc.contributor.authorMatsumura, Noriomien
dc.contributor.authorOgawa, Seishien
dc.contributor.authorUeno, Hidekien
dc.contributor.authorMandai, Masakien
dc.contributor.alternative鈴木, 悠ja
dc.contributor.alternative濱田, 航平ja
dc.contributor.alternative濱西, 潤三ja
dc.contributor.alternative植田, 彰彦ja
dc.contributor.alternative村上, 隆介ja
dc.contributor.alternative滝, 真奈ja
dc.contributor.alternative水野, 林ja
dc.contributor.alternative渡部,  光一ja
dc.contributor.alternative細江, 裕子ja
dc.contributor.alternative伊藤, 寛朗ja
dc.contributor.alternative山ノ井, 康二ja
dc.contributor.alternative吉富, 啓之ja
dc.contributor.alternative垣内, 伸之ja
dc.contributor.alternative山口, 建ja
dc.contributor.alternative小川, 誠司ja
dc.contributor.alternative上野, 英樹ja
dc.contributor.alternative万代, 昌紀ja
dc.date.accessioned2025-02-12T00:32:17Z-
dc.date.available2025-02-12T00:32:17Z-
dc.date.issued2025-03-
dc.identifier.urihttp://hdl.handle.net/2433/291709-
dc.description.abstractWith the incorporation of immune checkpoint inhibitors into the treatment of endometrial cancer (EC), a deeper understanding of the tumor immune microenvironment is critical. Tertiary lymphoid structures (TLSs) are considered favorable prognostic factors for EC, but the significance of their spatial distribution remains unclear. B cell receptor repertoire analysis performed using six TLS samples located at various distances from the tumor showed that TLSs in distal areas had more shared B cell clones with tumor-infiltrating lymphocytes. To comprehensively investigate the distribution of TLSs, we developed an artificial intelligence model to detect TLSs and determine their spatial locations in whole-slide images. Our model effectively quantified TLSs, and TLSs were detected in 69% of the patients with EC. We identified them as proximal or distal to the tumor margin and demonstrated that patients with distal TLSs (dTLSs) had significantly prolonged overall survival and progression-free survival (PFS) across multiple cohorts [hazard ratio (HR), 0.56; 95% confidence interval (CI), 0.36–0.88; p = 0.01 for overall survival; HR, 0.58; 95% CI, 0.40–0.84; p = 0.004 for PFS]. When analyzed by molecular subtype, patients with dTLSs in the copy-number-high EC subtype had significantly longer PFS (HR, 0.51; 95% CI, 0.29–0.91; p = 0.02). Moreover, patients with dTLSs had a higher response rate to immune checkpoint inhibitors (87.5 vs. 41.7%) and a trend toward improved PFS. Our findings indicate that the functions and prognostic implications of TLSs may vary with their locations, and dTLSs may serve as prognostic factors and predictors of treatment efficacy. This may facilitate personalized therapy for patients with EC.en
dc.language.isoeng-
dc.publisherSpringer Natureen
dc.rights© The Author(s) 2025en
dc.rightsThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/-
dc.subjectEndometrial canceren
dc.subjectTertiary lymphoid structureen
dc.subjectImmune checkpoint inhibitorsen
dc.subjectArtificial intelligenceen
dc.subjectB cell receptor repertoireen
dc.titleArtificial intelligence-based spatial analysis of tertiary lymphoid structures and clinical significance for endometrial canceren
dc.typejournal article-
dc.type.niitypeJournal Article-
dc.identifier.jtitleCancer Immunology, Immunotherapyen
dc.identifier.volume74-
dc.identifier.issue3-
dc.relation.doi10.1007/s00262-024-03929-6-
dc.textversionpublisher-
dc.identifier.artnum84-
dc.identifier.pmid39891665-
dcterms.accessRightsopen access-
dc.identifier.pissn0340-7004-
dc.identifier.eissn1432-0851-
出現コレクション:学術雑誌掲載論文等

アイテムの簡略レコードを表示する

Export to RefWorks


出力フォーマット 


このアイテムは次のライセンスが設定されています: クリエイティブ・コモンズ・ライセンス Creative Commons